在Budesonide治疗性结肠炎期间的细胞巨乳病毒结肠炎
Kana Tamazawa1,2, Masato Aizawa1, Jun Wada1,2
1Department of Gastroenterology, Fukushima Medical University Aizu Medical Center, Japan.
Internal medicine (Tokyo, Japan)
|January 14, 2026
概括
用于性结肠炎 (UC) 的布德索尼德MMX在一名患者中没有预防细胞巨乳病毒 (CMV) 结肠炎. 早期的CMV检测至关重要,如果UC在布塞尼德MMX治疗期间恶化.
科学领域:
- 胃肠病学 胃肠病学
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布德索尼德MMX是一种治疗轻度至中度性结肠炎 (UC) 的药物.
- 细胞巨乳病毒 (CMV) 大肠炎甚至可以发生在布索尼德治疗期间.
研究的目的:
- 报告在布塞索尼德MMX治疗UC期间出现的CMV大肠炎病例.
- 强调在恶化的UC病例中考虑CMV再激活的重要性.
主要方法:
- 一个69岁的妇女的病例报告,左侧UC.
- 临床表现:在布塞索尼德MMX治疗期间,腹和血恶化.
- 诊断方法:结肠镜检查,CMV pp65抗原血样检测,以及活检样本的免疫组织化学染色.
主要成果:
- 尽管患者接受了布德尼德MMX治疗,但患上了CMV大肠炎.
- CMV pp65抗原血是阳性的,活检证实了CMV感染.
- 用瓦尔甘西克洛维尔治疗导致了快速的临床改善和病毒清除.
结论:
- 局部作用的布索尼德MMX并不能消除CMV大肠炎的风险.
- 病毒复激活 (CMV) 可以发生在布德胺MMX治疗UC期间.
- 建议对UC患者进行早期的CMV测试,这些患者经历了布松胺MMX的临床恶化,以指导治疗决策.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
437
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
437
Inflammatory Bowel Disease I: Ulcerative Colitis
903
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
903
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.4K
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521


